Skip to main content
Premium Trial:

Request an Annual Quote

Anthrax Antimicrobial One Goal of Paradigm Genetics, VDDI Collaboration

NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

VDDI acquired the rights to the antimicrobial compounds, which researchers at the school claim target an important enzyme responsible for keeping alive certain microbes, in this case gram-positive bugs like Anthrax.

The agreement also gives Paradigm the option to co-develop with VDDI certain compounds for antibiotic and anti-fungal applications for applications in human health and agrochemistry.

Financial details of the collaboration were not disclosed.

This deal was originally funded with the help of a $6 million Defense Advanced Research Projects Agency grant to the UAB Center for Biophysical Sciences and Engineering, VDDI said. Next month, the US Department of Defense is set to award VDDI a multi-year contract worth $23 million to research and develop antibiotics that treat Anthrax.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.